Endogenous leukemia inhibitory factor attenuates endotoxin response

[1]  P. Heinrich,et al.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.

[2]  S. Melmed,et al.  Minireview: Neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules. , 2002, Endocrinology.

[3]  S. Melmed,et al.  Opposing effects of pituitary leukemia inhibitory factor and SOCS-3 on the ACTH axis response to inflammation. , 2002, American journal of physiology. Endocrinology and metabolism.

[4]  P. Patterson,et al.  Studies Using Leukemia Inhibitory Factor (LIF) Knockout Mice and a LIF Adenoviral Vector Demonstrate a Key Anti-Inflammatory Role for This Cytokine in Cutaneous Inflammation1 , 2001, The Journal of Immunology.

[5]  P. Patterson,et al.  Leukemia Inhibitory Factor, Interleukin 6, and Other Cytokines Using the GP130 Transducing Receptor: Roles in Inflammation and Injury , 1999, Stem cells.

[6]  M. Jordana,et al.  IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. , 1998, The Journal of clinical investigation.

[7]  B. Ryffel,et al.  Interferon-gamma enhances tumor necrosis factor-alpha production by inhibiting early phase interleukin-10 transcription. , 1996, European cytokine network.

[8]  B. Ryffel,et al.  Correction or Transfer of Immunodeficiency Due to TNF-LTα Deletion by Bone Marrow Transplantation , 1996, Molecular medicine.

[9]  D. Fraker,et al.  Endogenous D‐factor activity partially mediates the toxic but not the therapeutic effects of tumor necrosis factor , 1995, International journal of cancer.

[10]  E. Cullinan,et al.  LIF and Related Cytokines in the Regulation of Mammalian Development , 1995, Annals of the New York Academy of Sciences.

[11]  P. Waring,et al.  Leukemia inhibitory factor protects against experimental lethal Escherichia coli septic shock in mice. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P. Waring,et al.  Circulating leukemia inhibitory factor levels correlate with disease severity in meningococcemia. , 1994, The Journal of infectious diseases.

[13]  D. Fraker,et al.  D-factor/leukaemia inhibitory factor: evidence for its role as a mediator in acute and chronic inflammatory disease. , 1994, Cytokine.

[14]  J. Williams,et al.  Intratracheal injection of LPS and cytokines. V. LPS induces expression of LIF and LIF inhibits acute inflammation. , 1994, The American journal of physiology.

[15]  W. Fiers,et al.  Protection by alpha 1-acid glycoprotein against tumor necrosis factor- induced lethality , 1994, The Journal of experimental medicine.

[16]  G. Fantuzzi,et al.  Defective inflammatory response in interleukin 6-deficient mice , 1994, The Journal of experimental medicine.

[17]  M. Gerhart,et al.  Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing , 1994, Nature.

[18]  P. Vandenabeele,et al.  Interleukin‐10 controls interferon‐γ and tumor necrosis factor production during experimental endotoxemia , 1994, European journal of immunology.

[19]  B. Ryffel,et al.  Interferon gamma receptor deficient mice are resistant to endotoxic shock , 1994, The Journal of experimental medicine.

[20]  J. Devière,et al.  Interleukin-10 production during septicaemia , 1994, The Lancet.

[21]  C. Natanson,et al.  The third component of complement protects against Escherichia coli endotoxin-induced shock and multiple organ failure , 1994, The Journal of experimental medicine.

[22]  P. Ghezzi,et al.  Role of acute-phase proteins in interleukin-1-induced nonspecific resistance to bacterial infections in mice , 1993, Antimicrobial Agents and Chemotherapy.

[23]  J. Norton,et al.  Passive immunization of mice against D factor blocks lethality and cytokine release during endotoxemia , 1993, The Journal of experimental medicine.

[24]  P. Brûlet,et al.  Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation , 1993, Nature.

[25]  T. Mak,et al.  Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection , 1993, Cell.

[26]  B. Barton,et al.  Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model , 1993, Infection and immunity.

[27]  P. Waring,et al.  Leukemia inhibitory factor levels are elevated in septic shock and various inflammatory body fluids. , 1992, The Journal of clinical investigation.

[28]  J. Norton,et al.  Differentiation factor/leukemia inhibitory factor protection against lethal endotoxemia in mice: synergistic effect with interleukin 1 and tumor necrosis factor , 1992, The Journal of experimental medicine.

[29]  D. Hilton.  LIF: lots of interesting functions. , 1992, Trends in biochemical sciences.

[30]  J. Fierer,et al.  The acute‐phase response protects mice from D‐galactosamine sensitization to endotoxin and tumor necrosis factor–α , 1992, Hepatology.

[31]  J. Norton,et al.  Human recombinant interleukin-1 alpha protection against the lethality of endotoxin and experimental sepsis in mice. , 1991, The Journal of surgical research.

[32]  A. Wendel,et al.  In vivo evidence for protease-catalysed mechanism providing bioactive tumor necrosis factor alpha. , 1990, Biochemical pharmacology.

[33]  J. Vilček,et al.  IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. , 1989, Journal of immunology.

[34]  J. Norton,et al.  Prevention and treatment of endotoxin and sepsis lethality with recombinant human tumor necrosis factor. , 1989, Surgery.

[35]  A. Wendel,et al.  Tumor necrosis factor is a terminal mediator in galactosamine/endotoxin-induced hepatitis in mice. , 1989, Biochemical pharmacology.

[36]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[37]  C. Galanos,et al.  Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice , 1987, The Journal of experimental medicine.

[38]  B. Beutler,et al.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.

[39]  W. Reutter,et al.  Galactosamine-induced sensitization to the lethal effects of endotoxin. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. Keppler,et al.  Experimental hepatitis induced by D-galactosamine. , 1968, Experimental and molecular pathology.

[41]  P. Vandenabeele,et al.  The protective role of interleukin-10 in endotoxin shock. , 1994, Progress in clinical and biological research.

[42]  D. Metcalf.  The leukemia inhibitory factor (LIF). , 1991, International journal of cell cloning.

[43]  R. Williams,et al.  LIF: a molecule with divergent actions on myeloid leukaemic cells and embryonic stem cells. , 1989, Reproduction, fertility, and development.